Literature DB >> 32229719

Prognostic and predictive value of an immune infiltration signature in diffuse lower-grade gliomas.

Lai-Rong Song1,2,3,4, Jian-Cong Weng1,2,3,4, Cheng-Bei Li1, Xu-Lei Huo1,2,3,4, Huan Li1,3,4, Shu-Yu Hao1,2,3, Zhen Wu1,2,3,4, Liang Wang1,2,3,4, Da Li1,2,3,4, Jun-Ting Zhang1,2,3,4.   

Abstract

BACKGROUNDLower-grade gliomas (LGGs) vary widely in terms of the patient's overall survival (OS). There is no current, valid method that could exactly predict the survival. The effects of intratumoral immune infiltration on clinical outcome have been widely reported. Thus, we aim to develop an immune infiltration signature to predict the survival of LGG patients.METHODSWe analyzed 1216 LGGs from 5 public data sets, including 2 RNA sequencing data sets and 3 microarray data sets. Least absolute shrinkage and selection operator (LASSO) Cox regression was used to select an immune infiltration signature and build a risk score. The performance of the risk score was assessed in the training set (329 patients), internal validation set (140 patients), and 4 external validation sets (405, 118, 88, and 136 patients).RESULTSAn immune infiltration signature consisting of 20 immune metagenes was used to generate a risk score. The performance of the risk score was thoroughly verified in the training and validation sets. Additionally, we found that the risk score was positively correlated with the expression levels of TGF-β and PD-L1, which were important targets of combination immunotherapy. Furthermore, a nomogram incorporating the risk score, patient's age, and tumor grade was developed to predict the OS, and it performed well in all the training and validation sets (C-index: 0.873, 0.881, 0.781, 0.765, 0.721, and 0.753).CONCLUSIONThe risk score based on the immune infiltration signature has reliable prognostic and predictive value for patients with LGGs and is a potential biomarker for the cotargeting immunotherapy.FUNDINGThis work was supported by The National Natural Science Foundation of China (grant nos. 81472370 and 81672506), the Natural Science Foundation of Beijing (grant no. J180005), the National High Technology Research and Development Program of China (863 Program, grant no. 2014AA020610), and the National Basic Research Program of China (973 Program, grant no. 2014CB542006).

Entities:  

Keywords:  Bioinformatics; Brain cancer; Cancer immunotherapy; Genetics; Oncology

Mesh:

Substances:

Year:  2020        PMID: 32229719      PMCID: PMC7205440          DOI: 10.1172/jci.insight.133811

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  45 in total

1.  A Prognostic Signature for Lower Grade Gliomas Based on Expression of Long Non-Coding RNAs.

Authors:  Manjari Kiran; Ajay Chatrath; Xiwei Tang; Daniel Macrae Keenan; Anindya Dutta
Journal:  Mol Neurobiol       Date:  2018-11-03       Impact factor: 5.590

Review 2.  TGF-β signaling and its targeting for glioma treatment.

Authors:  Jianfeng Han; Christopher A Alvarez-Breckenridge; Qi-En Wang; Jianhua Yu
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

3.  Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma.

Authors:  Xin Hu; Emmanuel Martinez-Ledesma; Siyuan Zheng; Hoon Kim; Floris Barthel; Tao Jiang; Kenneth R Hess; Roel G W Verhaak
Journal:  Neuro Oncol       Date:  2017-06-01       Impact factor: 12.300

Review 4.  European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.

Authors:  Michael Weller; Martin van den Bent; Jörg C Tonn; Roger Stupp; Matthias Preusser; Elizabeth Cohen-Jonathan-Moyal; Roger Henriksson; Emilie Le Rhun; Carmen Balana; Olivier Chinot; Martin Bendszus; Jaap C Reijneveld; Frederick Dhermain; Pim French; Christine Marosi; Colin Watts; Ingela Oberg; Geoffrey Pilkington; Brigitta G Baumert; Martin J B Taphoorn; Monika Hegi; Manfred Westphal; Guido Reifenberger; Riccardo Soffietti; Wolfgang Wick
Journal:  Lancet Oncol       Date:  2017-05-05       Impact factor: 41.316

5.  RNA-Seq gene expression estimation with read mapping uncertainty.

Authors:  Bo Li; Victor Ruotti; Ron M Stewart; James A Thomson; Colin N Dewey
Journal:  Bioinformatics       Date:  2009-12-18       Impact factor: 6.937

Review 6.  The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis.

Authors:  Sandra S McAllister; Robert A Weinberg
Journal:  Nat Cell Biol       Date:  2014-08       Impact factor: 28.824

7.  The Immune Landscape of Cancer.

Authors:  Vésteinn Thorsson; David L Gibbs; Scott D Brown; Denise Wolf; Dante S Bortone; Tai-Hsien Ou Yang; Eduard Porta-Pardo; Galen F Gao; Christopher L Plaisier; James A Eddy; Elad Ziv; Aedin C Culhane; Evan O Paull; I K Ashok Sivakumar; Andrew J Gentles; Raunaq Malhotra; Farshad Farshidfar; Antonio Colaprico; Joel S Parker; Lisle E Mose; Nam Sy Vo; Jianfang Liu; Yuexin Liu; Janet Rader; Varsha Dhankani; Sheila M Reynolds; Reanne Bowlby; Andrea Califano; Andrew D Cherniack; Dimitris Anastassiou; Davide Bedognetti; Younes Mokrab; Aaron M Newman; Arvind Rao; Ken Chen; Alexander Krasnitz; Hai Hu; Tathiane M Malta; Houtan Noushmehr; Chandra Sekhar Pedamallu; Susan Bullman; Akinyemi I Ojesina; Andrew Lamb; Wanding Zhou; Hui Shen; Toni K Choueiri; John N Weinstein; Justin Guinney; Joel Saltz; Robert A Holt; Charles S Rabkin; Alexander J Lazar; Jonathan S Serody; Elizabeth G Demicco; Mary L Disis; Benjamin G Vincent; Ilya Shmulevich
Journal:  Immunity       Date:  2018-04-05       Impact factor: 43.474

8.  Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations.

Authors:  Xiao-Yang Liu; Noha Gerges; Andrey Korshunov; Nesrin Sabha; Dong-Anh Khuong-Quang; Adam M Fontebasso; Adam Fleming; Djihad Hadjadj; Jeremy Schwartzentruber; Jacek Majewski; Zhifeng Dong; Peter Siegel; Steffen Albrecht; Sidney Croul; David T W Jones; Marcel Kool; Martje Tonjes; Guido Reifenberger; Damien Faury; Gelareh Zadeh; Stefan Pfister; Nada Jabado
Journal:  Acta Neuropathol       Date:  2012-08-12       Impact factor: 15.887

9.  M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine.

Authors:  Karin M Knudson; Kristin C Hicks; Xiaoling Luo; Jin-Qiu Chen; Jeffrey Schlom; Sofia R Gameiro
Journal:  Oncoimmunology       Date:  2018-02-14       Impact factor: 8.110

10.  Immune Landscape of Colorectal Cancer Tumor Microenvironment from Different Primary Tumor Location.

Authors:  Longhui Zhang; Yuetao Zhao; Ying Dai; Jia-Nan Cheng; Zhihua Gong; Yi Feng; Chengdu Sun; Qingzhu Jia; Bo Zhu
Journal:  Front Immunol       Date:  2018-07-10       Impact factor: 7.561

View more
  7 in total

1.  Identification of a Nomogram with an Autophagy-Related Risk Signature for Survival Prediction in Patients with Glioma.

Authors:  Xiaofeng Fu; Luwei Hong; Haiying Gong; Guangjuan Kan; Pengfei Zhang; Ting-Ting Cui; Gonglin Fan; Xing Si; Jiang Zhu
Journal:  Int J Gen Med       Date:  2022-02-15

2.  Prognostic value of the ratio of carcinoembryonic antigen concentration to maximum tumor diameter in patients with stage II colorectal cancer.

Authors:  Xianzhe Li; Zhizhong Xiong; Minghao Xie; Qunsheng Huang; Longyang Jin; Shi Yin; Shuanggang Chen; Ping Lan; Lei Lian
Journal:  J Gastrointest Oncol       Date:  2021-08

3.  A Novel Classification Model for Lower-Grade Glioma Patients Based on Pyroptosis-Related Genes.

Authors:  Yusheng Shen; Hao Chi; Ke Xu; Yandong Li; Xisheng Yin; Shi Chen; Qian Yang; Miao He; Guohua Zhu; Xiaosong Li
Journal:  Brain Sci       Date:  2022-05-28

Review 4.  The immunology of low-grade gliomas.

Authors:  Alexander F Haddad; Jacob S Young; Jun Yeop Oh; Hideho Okada; Manish K Aghi
Journal:  Neurosurg Focus       Date:  2022-02       Impact factor: 4.332

5.  APOLLO: An accurate and independently validated prediction model of lower-grade gliomas overall survival and a comparative study of model performance.

Authors:  Jiajin Chen; Sipeng Shen; Yi Li; Juanjuan Fan; Shiyu Xiong; Jingtong Xu; Chenxu Zhu; Lijuan Lin; Xuesi Dong; Weiwei Duan; Yang Zhao; Xu Qian; Zhonghua Liu; Yongyue Wei; David C Christiani; Ruyang Zhang; Feng Chen
Journal:  EBioMedicine       Date:  2022-04-15       Impact factor: 11.205

6.  Identification of Gender- and Subtype-Specific Gene Expression Associated with Patient Survival in Low-Grade and Anaplastic Glioma in Connection with Steroid Signaling.

Authors:  Alex Hirtz; Nolwenn Lebourdais; Magalie Thomassin; Fabien Rech; Hélène Dumond; Hélène Dubois-Pot-Schneider
Journal:  Cancers (Basel)       Date:  2022-08-25       Impact factor: 6.575

7.  Construction and validation of a glioblastoma prognostic model based on immune-related genes.

Authors:  Kate Huang; Changjun Rao; Qun Li; Jianglong Lu; Zhangzhang Zhu; Chengde Wang; Ming Tu; Chaodong Shen; Shuizhi Zheng; Xiaofang Chen; Fangfang Lv
Journal:  Front Neurol       Date:  2022-07-28       Impact factor: 4.086

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.